Literature DB >> 33255262

PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer.

Nicola Curtin1, Péter Bai2,3,4.   

Abstract

The role of poly(ADP-ribose) polymerase-1 (PARP1) in DNA repair and as a potential target for anticancer therapy has been under investigation for more than 50 years [...].

Entities:  

Year:  2020        PMID： 33255262      PMCID： PMC7760776          DOI： 10.3390/cancers12123494

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN： 2072-6694            Impact factor:   6.639


  23 in total

Review 1.  Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.

Authors:  Florent Peyraud; Antoine Italiano
Journal:  Cancers (Basel)       Date:  2020-06-09       Impact factor: 6.639

Review 2.  The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer Cells.

Authors:  Malka Cohen-Armon
Journal:  Cancers (Basel)       Date:  2020-06-19       Impact factor: 6.639

Review 3.  Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy.

Authors:  Naveen Singh; S Louise Pay; Snehal B Bhandare; Udhaya Arimpur; Edward A Motea
Journal:  Cancers (Basel)       Date:  2020-04-14       Impact factor: 6.639

4.  ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms.

Authors:  Harriet E D Southgate; Lindi Chen; Deborah A Tweddle; Nicola J Curtin
Journal:  Cancers (Basel)       Date:  2020-04-28       Impact factor: 6.639

5.  Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells.

Authors:  Hannah L Smith; Lisa Prendergast; Nicola J Curtin
Journal:  Cancers (Basel)       Date:  2020-04-04       Impact factor: 6.639

6.  CAF-1 Subunits Levels Suggest Combined Treatments with PARP-Inhibitors and Ionizing Radiation in Advanced HNSCC.

Authors:  Francesco Morra; Francesco Merolla; Ida Picardi; Daniela Russo; Gennaro Ilardi; Silvia Varricchio; Federica Liotti; Roberto Pacelli; Luca Palazzo; Massimo Mascolo; Angela Celetti; Stefania Staibano
Journal:  Cancers (Basel)       Date:  2019-10-17       Impact factor: 6.639

Review 7.  The Multifactorial Role of PARP-1 in Tumor Microenvironment.

Authors:  Juan Manuel Martí; Mónica Fernández-Cortés; Santiago Serrano-Sáenz; Esteban Zamudio-Martinez; Daniel Delgado-Bellido; Angel Garcia-Diaz; Francisco Javier Oliver
Journal:  Cancers (Basel)       Date:  2020-03-20       Impact factor: 6.639

Review 8.  PARylation During Transcription: Insights into the Fine-Tuning Mechanism and Regulation.

Authors:  Zoltán G Páhi; Barbara N Borsos; Vasiliki Pantazi; Zsuzsanna Ujfaludi; Tibor Pankotai
Journal:  Cancers (Basel)       Date:  2020-01-11       Impact factor: 6.639

9.  Synergistic Anti-Tumour Effect of Syk Inhibitor and Olaparib in Squamous Cell Carcinoma: Roles of Syk in EGFR Signalling and PARP1 Activation.

Authors:  Duen-Yi Huang; Wei-Yu Chen; Chi-Long Chen; Nan-Lin Wu; Wan-Wan Lin
Journal:  Cancers (Basel)       Date:  2020-02-19       Impact factor: 6.639

Review 10.  PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation.

Authors:  Ahrum Min; Seock-Ah Im
Journal:  Cancers (Basel)       Date:  2020-02-08       Impact factor: 6.639
View more
  1 in total

1.  Poly(ADP-ribosyl)ating pathway regulates development from stem cell niche to longevity control.

Authors:  Guillaume Bordet; Elena Kotova; Alexei V Tulin
Journal:  Life Sci Alliance       Date:  2021-12-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.